Annual Report

Automotive SaaS firm MotorK posts a dramatic financial turnaround, achieving positive cash flow in H2 2025 by leveraging AI and a bold customer strategy.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Despite a full-year GAAP loss, AFC declares a dividend and shifts its strategy post-BDC conversion. Can it resolve legacy loans and find new growth?

Swiss sportswear giant On reports a landmark 2025 with record sales and ambitious goals, yet a currency hit complicates the bottom-line profit story.

Colombia's energy giant is set to reveal its 2025 performance, testing its diversification strategy against falling oil prices and high investor expectations.

The luxury marketplace achieved its first profitable quarter, a win for financial discipline. But with user metrics down, the focus now shifts to its 2026 growth plan.

The environmental services giant surpassed 2025 targets, driven by its GreenUp strategy, major acquisitions in water tech, and a renewed global push.

Legal tech firm DISCO reports strong growth fueled by a 600% surge in AI revenue, launching agentic AI and a disruptive new all-in-one pricing model.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Fresh off record profits, World Gym details its strategy for global growth, betting on AI health platforms and high-margin services to reshape the industry.

Amid private credit turmoil, SLR Investment Corp. posts solid 2025 results, leveraging a strategic pivot to asset-based lending for stability and returns.

AI marketing firm Zeta Global smashes records for the 18th straight quarter, raising guidance and projecting its first full year of GAAP profitability.

Fueled by policy incentives and strong demand, First Solar reports robust 2025 growth and accelerates its US factory expansion, cementing its market leadership.

Primoris Services Corp. posted a record $7.6B revenue for 2025, but a Q4 profit dip and project hurdles hint at challenges in its booming renewables arm.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

Appian flips from a major loss to GAAP profitability in 2025, driven by strong cloud revenue, key AI contracts, and a positive outlook for 2026.

As Cherry Hill Mortgage preps its 2025 results, investors eye dividends and strategy amid high interest rates and a challenging housing market.

Riding a wave of innovation and strategic shifts, the cruise wellness leader posts record earnings and projects over $1B in 2026 revenue.